Outcomes of plasma exchange for severe dilated cardiomyopathy in children

Area of Science:

• Cardiology
• Immunology
• Pediatrics

Background:

• Antimyocardial autoantibodies are implicated in dilated cardiomyopathy (DCM).
• Immunoabsorption therapy shows promise for adult DCM by reducing autoantibodies and improving cardiac function.
• The role and effectiveness of plasma exchange (PE) in pediatric DCM remain under-explored.

Purpose of the Study:

• To investigate the indications and efficacy of plasma exchange (PE) in children diagnosed with dilated cardiomyopathy (DCM).
• To evaluate the short-term and long-term outcomes of PE in pediatric DCM patients.

Main Methods:

• A single-center, retrospective study was conducted.
• Six pediatric patients with DCM, across different heart failure stages, received plasma exchange (PE).
• Cardiac function (left ventricular ejection fraction - LVEF) and functional class (New York Heart Association - NYHA) were assessed before and after PE.

Main Results:

• The first PE session resulted in transient improvements in LVEF and NYHA class in 83% and 80% of patients, respectively.
• The median duration of improved cardiac function after the initial PE was 8 months.
• Repeated PE sessions showed diminished efficacy, with improvements in LVEF and NYHA class observed in 50% and 25% of courses, respectively, lasting a median of 1 month.

Conclusions:

• Plasma exchange (PE) can provide temporary enhancement of cardiac function and clinical symptoms in pediatric patients with dilated cardiomyopathy (DCM).
• PE may be considered an adjunctive therapy for refractory pediatric DCM.
• PE should be viewed primarily as a temporizing measure, acting as a bridge to more definitive treatments such as ventricular assist device implantation or heart transplantation.